Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
ID: 356115Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $800K

Eligible Applicants

Public and State Controlled Institutions of Higher Education

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356115

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-018.html
Timeline
    Description

    The National Institutes of Health (NIH) is soliciting applications for a cooperative agreement to establish the Data Coordinating Center (DCC) for the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC). The primary objective of this initiative is to conduct a prospective longitudinal observational study on the incidence and clinical evolution of type 1 diabetes (T1D) following episodes of acute pancreatitis, with a focus on identifying immune and genetic risk factors. This research is critical for enhancing the understanding of diabetes development post-acute pancreatitis, addressing significant healthcare challenges, and guiding future research in diabetes and pancreatic disease. The total funding for the project is anticipated to be $5 million, with a maximum budget of $800,000 available annually for the DCC. Applications are due by November 19, 2024, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-018-Full-Announcement.html
    RFA-DK-25-018.html
    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is requesting a single-source cooperative agreement application from the Pennsylvania State University Hershey Medical Center to continue the Type 1 Diabetes in Acute Pancreatitis Consortium's Data Coordinating Center (T1DAPC-DCC). This initiative focuses on the prospective longitudinal observation of diabetes incidences following acute pancreatitis episodes, specifically targeting type 1 diabetes (T1D). The research aims to investigate the incidence, clinical evolution, and mechanisms of diabetes associated with acute pancreatitis through a variety of diagnostic methods and patient monitoring. Key components include the DCC's responsibility for logistical support, data management, and patient recruitment while ensuring data quality. The T1DAPC will consist of the DCC, a steering committee, and up to ten clinical centers, emphasizing collaboration among multidisciplinary teams. The total funding for the project is anticipated to be $5 million, with a maximum budget of $800,000 for the DCC annually. Applications are due by October 21, 2024, with a project period lasting up to five years. The initiative is crucial in enhancing understanding of diabetes development post-acute pancreatitis, addressing a significant healthcare challenge, and guiding future research in diabetes and pancreatic disease.
    Similar Opportunities
    Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition Funding Opportunity titled "Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers" (T1DAPC-CCs), aimed at establishing a clinical consortium to study diabetes incidence following acute pancreatitis episodes, with a focus on type 1 diabetes. This initiative seeks applications from previously funded Clinical Centers to continue a longitudinal observational study that investigates the incidence, etiology, and risk factors associated with diabetes emerging after acute pancreatitis, emphasizing collaboration among consortium members and effective data collection strategies. The funding amount is capped at $350,000 annually, with a project timeline extending up to five years, and applications are due by November 19, 2024, with the earliest anticipated award start in July 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source for Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement for the establishment of the Chronic Pancreatitis Clinical Research Consortium Data Coordinating Center (CPCRC-DCC) under funding opportunity RFA-DK-25-020. The primary objective is to facilitate ongoing studies on chronic pancreatitis, diabetes, and pancreatic cancer, focusing on data management, biomarker development, and clinical trial support for both pediatric and adult populations. This initiative is crucial for advancing the understanding of chronic pancreatitis and its associations with diabetes and pancreatic cancer, with an anticipated funding amount of $6.5 million over five years. Interested applicants must submit their proposals by 5:00 PM on October 19, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Coordinating Center for Type 1 Diabetes TrialNet (TNCC) through a cooperative agreement, aimed at supporting research initiatives focused on the prevention and intervention of type 1 diabetes (T1D). The TNCC will manage a variety of research projects, oversee data and sample management, and facilitate the selection of clinical centers necessary for conducting clinical studies related to T1D. This initiative underscores the federal commitment to advancing T1D research and treatment, with a total funding availability of approximately $29.5 million. Interested applicants must submit their proposals by October 17, 2024, and are required to include a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    The Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Chronic Pancreatitis Clinical Research Consortium (CPCRC), inviting U01 applications for Clinical Centers to conduct research on chronic pancreatitis, diabetes, and pancreatic cancer. The initiative aims to continue the consortium's work by collecting clinical data and biospecimens to identify biomarkers for risk stratification and disease progression, ultimately enhancing understanding and treatment of these conditions. With an estimated funding of $6.5 million for the 2025 fiscal year, applications are due by October 18, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for a cooperative agreement to support the continuation of the Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D) at the University of Pennsylvania. This initiative aims to enhance research on Type 1 Diabetes by systematically collecting and analyzing human pancreatic tissues and immune cells from patients, thereby advancing the understanding of disease mechanisms and identifying potential biomarkers for early intervention. The program is critical for fostering collaborative translational research within the Human Islet Research Network, which seeks innovative strategies to protect and replace functional human beta cell mass. The total funding available is $7.5 million over four years, with applications due by October 24, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), aimed at enhancing clinical trials focused on the prevention and early intervention of Type 1 Diabetes (T1D). The HUB will coordinate operations across various clinical centers to improve participant screening, recruitment, and retention, with a specific emphasis on increasing diversity among participants, particularly from minority populations. This initiative is critical for addressing the rising incidence of T1D and ensuring inclusivity in research efforts. The funding opportunity has an estimated budget of $750,000 per year from a total allocation of $1,000,000, with a maximum project duration of five years. Applications will be accepted starting September 16, 2024, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to be considered complete. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Data Coordinating Center (Collaborative U24 Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for a phased multi-site clinical trial aimed at preventing cardiovascular disease (CVD) in young adults with high lifetime risk, specifically through the establishment of a Data Coordinating Center (DCC). The DCC will be responsible for overall project coordination, administration, data management, and biostatistical support for the trial, which will evaluate the efficacy of pharmacological interventions against a control group while focusing on health equity and community engagement. This initiative is critical for addressing the rising incidence of CVD among young adults by employing innovative trial designs and strategies to enhance diverse perspectives. Applications are due by October 28, 2024, with a total budget allocation starting at $972,356 for fiscal year 2025, and interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.